Benefit from feedback mechanism
This article was originally published in Scrip
Executive Summary
One of the most commonly cited challenges faced by the pharmaceutical industry is the perception that the drug discovery and development regulatory burden is increasing. The claim that regulatory agencies are becoming more risk averse is used to explain all manner of regulatory delays. Now industry has an opportunity to have an input into the FDA's next strategic plan for regulatory science including future solutions.